Latest news with #StevenWheen
Business Insider
22-07-2025
- Business
- Business Insider
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Receives a Buy from Jarden
In a report released on July 18, Steven Wheen from Jarden maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per with a price target of A$40.55. The company's shares opened today at A$39.85. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Wheen is a 4-star analyst with an average return of 17.5% and a 58.95% success rate. Wheen covers the Healthcare sector, focusing on stocks such as CSL, Healius Limited, and Ramsay Health Care. Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per has an analyst consensus of Strong Buy, with a price target consensus of A$44.80.
Business Insider
14-07-2025
- Business
- Business Insider
CSL (CMXHF) Gets a Buy from Jarden
In a report released on July 9, Steven Wheen from Jarden maintained a Buy rating on CSL, with a price target of A$313.12. The company's shares closed last Friday at $153.96. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Wheen is a 4-star analyst with an average return of 16.7% and a 56.38% success rate. Wheen covers the Healthcare sector, focusing on stocks such as CSL, Healius Limited, and Regis Healthcare Ltd.. The word on The Street in general, suggests a Strong Buy analyst consensus rating for CSL with a $205.01 average price target, implying a 33.16% upside from current levels. In a report released on July 10, Morgans also maintained a Buy rating on the stock with a A$303.00 price target. Based on CSL's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $8.21 billion and a net profit of $2.01 billion. In comparison, last year the company earned a revenue of $8.36 billion and had a net profit of $2.91 billion
Business Insider
07-07-2025
- Business
- Business Insider
Sonic Healthcare Limited (SHL) Receives a Hold from Jarden
Jarden analyst Steven Wheen maintained a Hold rating on Sonic Healthcare Limited on July 3 and set a price target of A$29.84. The company's shares opened today at A$27.32. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Wheen covers the Healthcare sector, focusing on stocks such as CSL, Healius Limited, and Regis Healthcare Ltd.. According to TipRanks, Wheen has an average return of 17.5% and a 56.99% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sonic Healthcare Limited with a A$30.70 average price target, which is a 12.37% upside from current levels. In a report released on June 30, Jefferies also maintained a Hold rating on the stock with a A$30.30 price target. SHL market cap is currently A$13.42B and has a P/E ratio of 23.85. Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SHL in relation to earlier this year.
Business Insider
18-06-2025
- Business
- Business Insider
Jarden Reaffirms Their Buy Rating on CSL (CMXHF)
Jarden analyst Steven Wheen maintained a Buy rating on CSL (CMXHF – Research Report) yesterday and set a price target of A$317.61. The company's shares closed yesterday at $148.56. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Wheen is a 4-star analyst with an average return of 16.5% and a 53.26% success rate. Wheen covers the Healthcare sector, focusing on stocks such as CSL, Healius Limited, and Regis Healthcare Ltd.. Currently, the analyst consensus on CSL is a Strong Buy with an average price target of $203.87, implying a 37.23% upside from current levels. In a report released today, Morgan Stanley also maintained a Buy rating on the stock with a A$303.00 price target. The company has a one-year high of $215.00 and a one-year low of $137.40. Currently, CSL has an average volume of 1,418.
Business Insider
10-06-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Bio-Rad Laboratories (BIO) and Ramsay Health Care (OtherRMSYF)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bio-Rad Laboratories (BIO – Research Report) and Ramsay Health Care (RMSYF – Research Report). Confident Investing Starts Here: Bio-Rad Laboratories (BIO) RBC Capital analyst Conor McNamara maintained a Buy rating on Bio-Rad Laboratories on June 5 and set a price target of $381.00. The company's shares closed last Monday at $225.56. According to McNamara 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -22.5% and a 18.4% success rate. McNamara covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, SOPHiA GENETICS, and Exact Sciences. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bio-Rad Laboratories with a $316.40 average price target. In a report released today, Steven Wheen from Jarden maintained a Hold rating on Ramsay Health Care, with a price target of A$44.05. The company's shares closed last Thursday at $24.00. According to Wheen is ranked #1103 out of 9627 analysts. The word on The Street in general, suggests a Hold analyst consensus rating for Ramsay Health Care with a $25.09 average price target.
